



SGO Annual Meeting on Women's Cancer®

# NEW ORLEANS

March 24 – 27, 2018

## Oral Abstracts and Featured Posters



Society of Gynecologic Oncology

### Saturday, March 24, 2018

#### OPENING SCIENTIFIC PLENARY SESSION I ABSTRACTS 1-6

##### Abstract 1

**GOG 3007, a randomized phase II (RP2) trial of everolimus and letrozole (EL) or hormonal therapy (medroxyprogesterone acetate/tamoxifen, PT) in women with advanced, persistent or recurrent endometrial carcinoma (EC): A GOG Foundation study**

B. Slomovitz<sup>1,2</sup>, V.L. Filiaci<sup>3</sup>, R.L. Coleman<sup>4</sup>, J.L. Walker<sup>5</sup>, A.C. Fleury<sup>6</sup>, L.L. Holman<sup>7</sup> and D.S. Miller<sup>8</sup>

*<sup>1</sup>University of Miami Sylvester Comprehensive Cancer Center, Miami, FL, USA, <sup>2</sup>University of Miami Miller School of Medicine, Miami, FL, USA, <sup>3</sup>Gynecologic Oncology Group Statistical and Data Center, Buffalo, NY, USA, <sup>4</sup>The University of Texas MD Anderson Cancer Center, Houston, TX, USA, <sup>5</sup>The University of Oklahoma, Oklahoma City, OK, USA, <sup>6</sup>Women's Cancer Center of Nevada, Las Vegas, NV, USA, <sup>7</sup>The University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA, <sup>8</sup>The University of Texas Southwestern Medical Center, Dallas, TX, USA*

##### Abstract 2

**Novel intrauterine polymer system delivers everolimus at biologically active levels in rats**

J.A. Dottino<sup>1</sup>, Y. Jiang<sup>1</sup>, S. Shah<sup>2</sup>, J. Celestino<sup>1</sup>, E. Watson<sup>3</sup>, Q. Zhang<sup>1</sup>, G. Chisholm<sup>1</sup>, J. Burks<sup>1</sup>, A. Mikos<sup>3</sup>, K.H. Lu<sup>1</sup> and M. Yates<sup>1</sup>

*<sup>1</sup>The University of Texas MD Anderson Cancer Center, Houston, TX, USA, <sup>2</sup>Baylor College of Medicine, Houston, TX, USA, <sup>3</sup>Rice University, Houston, TX, USA*

##### Abstract 3

**Disparities in the allocation of research funding to gynecologic cancers demonstrated by funding to lethality scores**

R. Spencer<sup>1</sup>, L.W. Rice<sup>1</sup>, C.Y. Ye<sup>1</sup> and S. Uppal<sup>2</sup>

*<sup>1</sup>University of Wisconsin School of Medicine and Public Health, Madison, WI, USA, <sup>2</sup>University of Michigan Health Systems, Ann Arbor, MI, USA*

Abstract 4

**Changes in the Affordable Care Act affecting women: Fiscal 2014-2017**

E.J. Pavlik<sup>1</sup>, M. Geiger<sup>2</sup>, J.C. Dillon<sup>2</sup>, C. Sheffer<sup>2</sup>, T.E. Pavlik<sup>2</sup>, E.A. Harvey<sup>2</sup>, B. Wagner<sup>2</sup>, Q. Yu<sup>2</sup>, L.A. Baldwin<sup>3</sup> and M.S. Johnson<sup>3</sup>

<sup>1</sup>University of Kentucky, Lexington, KY, USA, <sup>2</sup>University of Kentucky College of Medicine, Lexington, KY, USA, <sup>3</sup>University of Kentucky Medical Center, Lexington, KY, USA

Abstract 5

**The Affordable Care Act reduced racial and socioeconomic disparities in access to health insurance among women diagnosed with a gynecologic malignancy**

H.A. Moss, L.J. Havrilesky and J. Chino

*Duke University Medical Center, Durham, NC, USA*

Abstract 6

**Participation in clinical trials may overcome health disparities in the treatment of advanced or recurrent epithelial ovarian cancer**

K.B. Patel<sup>1</sup>, A. Pyrzak<sup>2</sup>, H. Williams<sup>2</sup>, H. Coste<sup>1</sup>, L.F. Zhang<sup>1</sup>, R. Sadek<sup>1</sup>, J.J. Wallbillich<sup>1</sup>, S. Ghamande<sup>2</sup> and B.J. Rungruang<sup>1</sup>

<sup>1</sup>Medical College of Georgia, Augusta, GA, USA, <sup>2</sup>Georgia Regents University, Augusta, GA, USA

**SCIENTIFIC PLENARY SESSION II: CONTEMPORARY CHALLENGES  
ABSTRACTS 7-13**

**10:30 a.m. – 12:00 p.m.**

Abstract 7

**Tackling the opioid crisis: Implementation of an ultra-restrictive opioid prescription protocol in patients undergoing major gynecologic surgery radically decreased dispensed opioid without reducing pain control**

J.E. Mark<sup>1</sup>, D. Phoenix<sup>1</sup>, C.A. Gutierrez<sup>2</sup>, K. Morrell<sup>1</sup>, K.H. Eng<sup>1</sup>, P.C. Mayor<sup>1</sup>, S.N. Akers<sup>1</sup>, S.B. Lele<sup>1</sup>, K. Odunsi<sup>1</sup>, O. DeLeon<sup>1</sup>, P.J. Frederick<sup>1</sup> and E. Zsiros<sup>1</sup>

<sup>1</sup>Roswell Park Cancer Institute, Buffalo, NY, USA, <sup>2</sup>University of Buffalo, Buffalo, NY, USA

Abstract 8

**Opioid use in gynecology oncology patients after minimally invasive hysterectomy**

E. Weston<sup>1</sup>, C. Raker<sup>2</sup>, D. Huang<sup>3</sup>, A.B. Parker<sup>2</sup>, K.M. Robison<sup>2</sup> and C.A. Mathews<sup>2</sup>

<sup>1</sup>Johns Hopkins School of Medicine, Baltimore, MD, USA, <sup>2</sup>Women & Infants Hospital, Brown University, Providence, RI, USA, <sup>3</sup>University of California, San Francisco, San Francisco, CA, USA

Abstract 9

**Variation of cost and resource utilization associated with the surgical management of women with ovarian cancer**

J.A. Rauh-Hain<sup>1</sup>, A. Melamed<sup>2</sup>, L.A. Meyer<sup>1</sup> and M.G. del Carmen<sup>3</sup>

<sup>1</sup>The University of Texas MD Anderson Cancer Center, Houston, TX, USA, <sup>2</sup>Massachusetts General Hospital, Boston, MA, USA, <sup>3</sup>Massachusetts General Hospital/Harvard University, Boston, MA, USA

**Abstract 10****Development of an alternative payment model (APM) for early-stage cervical cancer: Opportunities to reduce cost and improve quality**

J.D. Wright<sup>1</sup>, L.J. Havrilesky<sup>2</sup>, R.D. Alvarez<sup>3</sup>, D.E. Cohn<sup>4</sup>, Y. Huang<sup>1</sup>, L.R. Boyd<sup>5</sup> and E.M. Ko<sup>6</sup>  
<sup>1</sup>Columbia University College of Physicians and Surgeons, New York, NY, USA, <sup>2</sup>Duke University Medical Center, Durham, NC, USA, <sup>3</sup>University of Alabama at Birmingham, Birmingham, AL, USA, <sup>4</sup>The Ohio State University, James Cancer Hospital, Columbus, OH, USA, <sup>5</sup>New York University School of Medicine, New York, NY, USA, <sup>6</sup>University of Pennsylvania, Philadelphia, PA, USA

**Abstract 11****GOG 244, the lymphedema and gynecologic cancer (LEG) study: Incidence and risk factors in newly diagnosed patients**

J.W. Carlson<sup>1</sup>, J. Kauderer<sup>2</sup>, A. Hutson<sup>2</sup>, J. Carter<sup>3</sup>, J.A. Armer<sup>4</sup>, S. Lockwood<sup>5</sup>, S. Nolte<sup>6</sup>, L. Wenzel<sup>7</sup>, J.L. Walker<sup>8</sup>, A.C. Fleury<sup>9</sup>, A.J. Bonebrake<sup>10</sup>, J.T. Soper<sup>11</sup>, C.A. Mathews<sup>12</sup>, O. Zivanovic<sup>3</sup>, W.E. Richards<sup>13</sup>, D.S. Alberts<sup>14</sup> and R.R. Barakat<sup>3</sup>  
<sup>1</sup>Mercy Clinic - Women's Oncology, Springfield, MO, USA, <sup>2</sup>Gynecologic Oncology Group Statistical and Data Center, Buffalo, NY, USA, <sup>3</sup>Memorial Sloan Kettering Cancer Center, New York, NY, USA, <sup>4</sup>University of Missouri, Columbia, MO, USA, <sup>5</sup>SGNO, Fort Worth, TX, USA, <sup>6</sup>Abington Memorial Hospital, Abington, PA, USA, <sup>7</sup>University of California, Irvine, Irvine, CA, USA, <sup>8</sup>The University of Oklahoma, Oklahoma City, OK, USA, <sup>9</sup>Women's Cancer Center of Nevada, Las Vegas, NV, USA, <sup>10</sup>Cox Health, Springfield, MO, USA, <sup>11</sup>University of North Carolina at Chapel Hill, Chapel Hill, NC, USA, <sup>12</sup>Women & Infants Hospital, Brown University, Providence, RI, USA, <sup>13</sup>Lewis Cancer & Research Pavilion @ St. Joseph's Candler, Savannah, GA, USA, <sup>14</sup>The University of Arizona Cancer Center, Tucson, AZ, USA

**Abstract 12****The FILM Trial: A randomized phase III multicenter study assessing near infrared fluorescence in the identification of sentinel lymph nodes (SLN)**

M. Frumovitz<sup>1</sup>, M. Plante<sup>2</sup>, P.S. Lee<sup>3</sup>, S. Sandadi Sr.<sup>4</sup>, J.F. Lilja<sup>5</sup>, P.F. Escobar<sup>6</sup>, L.T. Gien<sup>7</sup>, M.F. Munsell<sup>1</sup> and N.R. Abu-Rustum<sup>4</sup>  
<sup>1</sup>The University of Texas MD Anderson Cancer Center, Houston, TX, USA, <sup>2</sup>Laval University, L'Hotel-Dieu de Quebec, Quebec City, QC, Canada, <sup>3</sup>Duke University Medical Center, Durham, NC, USA, <sup>4</sup>Memorial Sloan Kettering Cancer Center, New York, NY, USA, <sup>5</sup>Bay Area Gynecology Oncology, San Jose, CA, USA, <sup>6</sup>Instituto Gyneco-Oncologico, Caguas, PR, USA, <sup>7</sup>Sunnybrook Odette Cancer Center, Toronto, ON, Canada

**Abstract 13****Sentinel lymph node (SLN) isolated tumor cells (ITCs) in otherwise stage I/II endometrioid endometrial cancer: To treat or not to treat?**

F.J. Backes<sup>1</sup>, A.S. Felix<sup>2</sup>, J. Grégoire<sup>3</sup>, M. Plante<sup>4</sup>, S.A. Sullivan<sup>5</sup>, E.C. Rossi<sup>5</sup>, E.J. Tanner III<sup>6</sup>, K.I. Stewart<sup>7</sup>, P.T. Soliman<sup>7</sup>, D. Cohen<sup>2</sup>, R.W. Holloway<sup>8</sup>, N.R. Abu-Rustum<sup>9</sup> and M.M. Leitao Jr.<sup>9</sup>  
<sup>1</sup>The Ohio State University, James Cancer Hospital, Columbus, OH, USA, <sup>2</sup>The Ohio State University, Columbus, OH, USA, <sup>3</sup>L'Hotel-Dieu de Quebec, Quebec City, QC, Canada, <sup>4</sup>Laval University, L'Hotel-Dieu de Quebec, Quebec City, QC, Canada, <sup>5</sup>University of North Carolina at Chapel Hill, Chapel Hill, NC, USA, <sup>6</sup>Johns Hopkins Hospital, Baltimore, MD, USA, <sup>7</sup>The University of Texas MD Anderson Cancer Center, Houston, TX, USA, <sup>8</sup>Florida Hospital Cancer Institute, Orlando, FL, USA, <sup>9</sup>Memorial Sloan Kettering Cancer Center, New York, NY, USA

## EDUCATION FORUM III: IMMUNOTHERAPY

### ABSTRACT 14-15

3:30 p.m. – 5:00 p.m.

#### Abstract 14

**An *in vitro* evaluation of neoantigens derived from gene fusion events in ovarian cancer patients**

M.S. Ross<sup>1</sup>, M. Tianzhou<sup>2</sup>, N. Priedigkeit<sup>2</sup>, L. Zhang<sup>2</sup>, G. Tseng<sup>3</sup>, A.V. Lee<sup>2</sup>, R.P. Edwards<sup>1</sup> and A. Vlad<sup>4</sup>

<sup>1</sup>Magee-Womens Hospital of UPMC, Pittsburgh, PA, USA, <sup>2</sup>University of Pittsburgh/Magee-Womens Hospital, Pittsburgh, PA, USA, <sup>3</sup>University of Pittsburgh, Pittsburgh, PA, USA, <sup>4</sup>Magee-Womens Research Institute, Pittsburgh, PA, USA

#### Abstract 15

**Adverse events and responses in patients with recurrent ovarian cancer undergoing early-phase immune checkpoint inhibitor clinical trials**

E.M. Hinchcliff, D. Hong, H. Le, G. Chisholm, R. Iyer, A. Naing and A.A. Jazaeri

*The University of Texas MD Anderson Cancer Center, Houston, TX, USA*

## EDUCATION FORUM III: IMMUNOTHERAPY

### ABSTRACT 16

3:30 p.m. – 5:00 p.m.

#### Abstract 16

**A cost-effectiveness analysis of three PARP inhibitors for maintenance therapy in platinum-sensitive recurrent ovarian cancer**

A.Y. Liu<sup>1</sup>, J.G. Cohen<sup>1</sup>, C. Walsh<sup>2</sup>, C.H. Holschneider<sup>3</sup> and A.K. Sinno<sup>1</sup>

<sup>1</sup>University of California, Los Angeles, Los Angeles, CA, USA, <sup>2</sup>Cedars-Sinai Medical Center, Los Angeles, CA, USA, <sup>3</sup>David Geffen School of Medicine at UCLA, Los Angeles, CA, USA

## Sunday, March 25, 2018

## SUNRISE SEMINAR I: POPULATION HEALTH STRATEGIES

### ABSTRACT 17

6:30 a.m. – 7:30 a.m.

#### Abstract 17

**Utilizing the patient-reported outcomes measurement information system (PROMIS) to improve referral to ancillary support services for severely symptomatic patients with gynecologic cancer**

G.M. Gressel<sup>1</sup>, S.M. Dioun<sup>1</sup>, M. Richley<sup>1</sup>, A.R. Van Arsdale<sup>2</sup>, S. Isani<sup>3</sup>, N.S. Nevadunsky<sup>2</sup>, D. Smotkin<sup>2</sup>, H.O. Smith<sup>2</sup>, D.Y.S. Kuo<sup>2</sup> and A.P. Novetsky<sup>2</sup>

<sup>1</sup>Montefiore Medical Center, Bronx, NY, USA, <sup>2</sup>Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY, USA, <sup>3</sup>Albert Einstein College of Medicine, New York, NY, USA

## SCIENTIFIC PLENARY III: PARP-POURRI

### ABSTRACTS 18-21

8:00 a.m. – 8:50 a.m.

#### Abstract 18

**PARP 7 has a significant role in overall survival of patients with ovarian cancer**

L.H. Palavalli Parsons and J.S. Lea

*The University of Texas Southwestern Medical Center, Dallas, TX, USA*

#### Abstract 19

**Bevacizumab, TKI, or PARPi? A targeted approach using composite value-based endpoints and biomarkers to individualize care for platinum-sensitive recurrent ovarian cancer (PSROC)**

J.R. Foote<sup>1</sup>, A. Alvarez-Secord<sup>1</sup>, M.I. Liang<sup>2</sup>, J.A. Ehrisman<sup>1</sup>, D.E. Cohn<sup>3</sup>, E. Jewell<sup>4</sup> and L.J. Havrilesky<sup>1</sup>

<sup>1</sup>Duke University Medical Center, Durham, NC, USA, <sup>2</sup>David Geffen School of Medicine at UCLA, Los Angeles, CA, USA, <sup>3</sup>The Ohio State University, James Cancer Hospital, Columbus, OH, USA, <sup>4</sup>Memorial Sloan Kettering Cancer Center, New York, NY, USA

#### Abstract 20

**Safety and dose modification for patients with low body weight receiving niraparib in the ENGOT-OV16/NOVA phase III trial**

R. Lord<sup>1</sup>, M.R. Mirza<sup>2</sup>, L. Woelber<sup>3</sup>, A. Lesoin<sup>4</sup>, M.J. Pineda<sup>5</sup>, U. Peen<sup>6</sup>, S.J. Hazard<sup>7</sup> and U.A. Matulonis<sup>8</sup>

<sup>1</sup>National Cancer Research Institute (NCRI) and Clatterbridge Cancer Center, Wirral, United Kingdom, <sup>2</sup>The Nordic Society of Gynecological Oncology (NSGO) and Rigshospitalet-Copenhagen University Hospital, Copenhagen, Denmark, <sup>3</sup>Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) and University Medical Center Hamburg - Eppendorf, Hamburg, Germany, <sup>4</sup>Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO) and Centre Oscar Lambret Department de Cancérologie Sénologique, Lille, France, <sup>5</sup>Ironwood Cancer and Research Center, Mesa, AZ, USA, <sup>6</sup>NSGO and Herlev Hospital, Herlev, Denmark, <sup>7</sup>Tesaro, Inc., Waltham, MA, USA, <sup>8</sup>Dana-Farber Cancer Institute, Boston, MA, USA

#### Abstract 21

**Are FDA-approved PARPi cost-effective as maintenance treatment of platinum-sensitive recurrent ovarian cancer?**

J.A. Dottino<sup>1</sup>, H.A. Moss<sup>2</sup>, K.H. Lu<sup>1</sup>, A.A. Secord<sup>3</sup> and L.J. Havrilesky<sup>2</sup>

<sup>1</sup>The University of Texas MD Anderson Cancer Center, Houston, TX, USA, <sup>2</sup>Duke University Medical Center, Durham, NC, USA, <sup>3</sup>Duke Cancer Institute, Durham, NC, USA

## SCIENTIFIC PLENARY IV: CURRENT TRIALS, EMERGING TARGETS

### ABSTRACTS 22-26

1:45 p.m. – 2:30 p.m.

#### Abstract 22

**Randomized phase II trial of carboplatin-paclitaxel compared to carboplatin-paclitaxel-trastuzumab in advanced or recurrent uterine serous carcinomas that overexpress Her2/neu (NCT01367002)**

A.D. Santin<sup>1</sup> and A.N. Fader<sup>2</sup>

<sup>1</sup>Yale University School of Medicine, New Haven, CT, USA, <sup>2</sup>Johns Hopkins School of Medicine, Baltimore, MD, USA

**Abstract 23****Predictive biomarkers of endometrial cancer response: Results from NRG Oncology/ Gynecologic Oncology Group study 86P**

D.A. Levine<sup>1</sup>, D.S. Dizon<sup>2</sup>, J.W. Carlson<sup>3</sup>, V.L. Filiaci<sup>4</sup>, M.A. Powell<sup>5</sup>, A.A. Secord<sup>6</sup>, K.S. Tewari<sup>7</sup>, D.P. Bender<sup>8</sup>, D.M. O'Malley<sup>9</sup>, A.R. Stuckey<sup>10</sup>, K.N. Moore<sup>11</sup>, S.B. Dewdney<sup>12</sup>, J. Gao<sup>13</sup>, F. Dao<sup>1</sup>, R.A. Soslow<sup>13</sup>, H.A. Lankes<sup>4</sup> and C.A. Aghajanian<sup>14</sup>

<sup>1</sup>NYU Langone Health, New York, NY, USA, <sup>2</sup>Massachusetts General Hospital Cancer Center, Boston, MA, USA, <sup>3</sup>Mercy Clinic - Women's Oncology, Springfield, MO, USA, <sup>4</sup>Gynecologic Oncology Group Statistical and Data Center, Buffalo, NY, USA, <sup>5</sup>Washington University School of Medicine in St. Louis, St. Louis, MO, USA, <sup>6</sup>Duke Cancer Institute, Durham, NC, USA, <sup>7</sup>University of California Irvine Medical Center, Orange, CA, USA, <sup>8</sup>University of Iowa Hospitals and Clinics, Iowa City, IA, USA, <sup>9</sup>The Ohio State University, James Cancer Hospital, Columbus, OH, USA, <sup>10</sup>Women & Infants Hospital, Brown University, Providence, RI, USA, <sup>11</sup>The University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA, <sup>12</sup>Rush University Medical Center, Chicago, IL, USA, <sup>13</sup>Memorial Sloan Kettering Cancer Center, New York, NY, USA, <sup>14</sup>Weill Cornell Medical College, New York, NY, USA

**Abstract 24****IAP antagonism enhances anti-tumor activity of docetaxel or panobinostat in ovarian cancer cell lines**

K.P. Zelig<sup>1</sup>, F. Ning<sup>2</sup>, L. Hernandez<sup>3</sup>, T. Smyth<sup>4</sup>, G. Ward<sup>4</sup> and C.M. Annunziata<sup>3</sup>

<sup>1</sup>Walter Reed National Military Medical Center, Bethesda, MD, USA, <sup>2</sup>National Institutes of Health, Bethesda, MD, USA, <sup>3</sup>National Cancer Institute, Bethesda, MD, USA, <sup>4</sup>Astex Pharmaceuticals, Cambridge, United Kingdom

**Abstract 25****Development of a high-affinity anti-galectin-3 antibody targeting interactions between MUC16/ CA-125 and galectin-3 to inhibit oncogenic properties in serous ovarian cancer**

M. Stasenکو, T.D. Rao, F. Weis-Garcia and D. Spriggs

Memorial Sloan Kettering Cancer Center, New York, NY, USA

**Abstract 26****Targeting the TIE2 pathway with a novel small molecule vascular endothelial protein tyrosine phosphatase (VE-PTP) inhibitor in high-grade serous ovarian cancer**

L.P. Cobb<sup>1</sup>, A. Rickard<sup>2</sup>, J. Herbert<sup>2</sup>, G. Hanna<sup>2</sup>, G. Palmer<sup>2</sup>, S. Siamakpour-Reihani<sup>2</sup>, Z. Huang<sup>2</sup>, K. Peters<sup>3</sup>, C. Kontos<sup>2</sup>, A. Berchuck<sup>4</sup> and A.A. Secord<sup>5</sup>

<sup>1</sup>Duke University School of Medicine, Durham, NC, USA, <sup>2</sup>Duke University, Durham, NC, USA, <sup>3</sup>Aerpio Therapeutics, Cincinnati, OH, USA, <sup>4</sup>Duke University Medical Center, Durham, NC, USA, <sup>5</sup>Duke Cancer Institute, Durham, NC, USA

**EDUCATION FORUM V: PALLIATIVE CARE****ABSTRACT 27****3:30 p.m. – 5:00 p.m.****Abstract 27****Trends in place of death among gynecologic cancer patients in the United States**

K. Hicks-Courant<sup>1</sup>, A. Melamed<sup>2</sup> and J.A.A. Rauh-Hain<sup>2</sup>

<sup>1</sup>Tufts Medical Center, Boston, MA, USA, <sup>2</sup>Massachusetts General Hospital, Boston, MA, USA

**Monday, March 26, 2018**

**SUNRISE SEMINAR V: HEALTH CARE ECONOMICS**

**ABSTRACT 28**

**6:30 a.m. – 7:30 a.m.**

**Abstract 28**

**Indicated presurgical testing is a priority to achieve high-quality, cost-effective oncologic health care delivery**

G.J. Gardner, H. Weiss, A. Klotz, S. Ogden, D. Boccamazzo, J. Hagerty-Paglia, N.R. Abu-Rustum, K. Sepkowitz, G. Fischer and J. Drebin

*Memorial Sloan Kettering Cancer Center, New York, NY, USA*

**SCIENTIFIC PLENARY V: FARR NEZHAT SURGICAL INNOVATION SESSION  
SURGICAL DECISION MAKING IN ADVANCED OVARIAN CANCER**

**ABSTRACT 29**

**9:20 a.m. – 10:30 a.m.**

**Abstract 29**

**Moving beyond “complete surgical resection” and “optimal”: Is low-volume residual disease another option?**

B.L. Manning-Geist<sup>1,2</sup>, K. Hicks-Courant<sup>3</sup>, A.A. Gockley<sup>4</sup>, R.M. Clark<sup>4</sup>, M.G. del Carmen<sup>5</sup>, J.O. Schorge<sup>2</sup>, N.S. Horowitz<sup>6</sup>, R.S. Berkowitz<sup>6</sup>, M.G. Muto<sup>7</sup> and M.J. Worley Jr.<sup>8</sup>

*<sup>1</sup>Brigham and Women's Hospital/Harvard Medical School, Boston, MA, USA, <sup>2</sup>Massachusetts General Hospital, Boston, MA, USA, <sup>3</sup>Tufts Medical Center, Boston, MA, USA, <sup>4</sup>Harvard Medical School, Boston, MA, USA, <sup>5</sup>Massachusetts General Hospital/Harvard University, Boston, MA, USA, <sup>6</sup>Brigham and Women's Hospital, Boston, MA, USA, <sup>7</sup>Dana-Farber Cancer Institute, Boston, MA, USA, <sup>8</sup>Brigham and Women's Hospital/Harvard University, Boston, MA, USA*

**FOCUSED PLENARY I: PRECLINICAL AND TRANSLATIONAL MEDICINE  
ABSTRACTS 30-34**

**11:30 a.m. – 12:30 p.m.**

**Abstract 30**

**Simvastatin has anti-tumorigenic effects in endometrial cancer via reversal of obesity-driven upregulation of lipid biosynthesis**

L. West<sup>1</sup>, L.H. Clark<sup>1</sup>, S.R. Pierce<sup>1</sup>, Y. Yin<sup>1</sup>, Z. Fang<sup>1</sup>, D. Lee<sup>2</sup>, C. Zhou<sup>1</sup> and V.L. Bae-Jump<sup>1</sup>

*<sup>1</sup>University of North Carolina at Chapel Hill, Chapel Hill, NC, USA, <sup>2</sup>Omic Insight, LCC, Durham, NC, USA*

**Abstract 31**

**Combination metformin and simvastatin treatment induces apoptosis in endometrial cancer cells *in vitro* and reduces premalignant and malignant endometrial lesions *in vivo***

J.S. Kim<sup>1,2</sup>, J. Turbov<sup>2</sup>, R. Rosales<sup>2</sup>, W.G. Watkin<sup>1,2</sup>, L.G. Thaete<sup>1,2</sup> and G.C. Rodriguez<sup>1,2</sup>

*<sup>1</sup>The University of Chicago Medicine, Chicago, IL, USA, <sup>2</sup>NorthShore University HealthSystem, Evanston, IL, USA*

**Abstract 32**

**Overcoming platinum resistance in ovarian cancer by targeting pregnancy-associated plasma protein-a**

D. Torres, X. Hou, L.K. Bale, E.P. Heinzen, M.J. Maurer, Q. Zhang, C.A. Conover and S.J. Werooha  
*Mayo Clinic, Rochester, MN, USA*

- Abstract 33**      **Expression of dopamine receptor D2 in endometrial tumors and the impact of DRD2 blockade on cancer proliferation**
- S.R. Pierce<sup>1</sup>, M. Asher<sup>1</sup>, Z. Fang<sup>1</sup>, L. West<sup>1</sup>, Y. Yin<sup>1</sup>, V. Prabhu<sup>2</sup>, C. Xu<sup>1</sup>, C. Zhou<sup>1</sup> and V.L. Bae-Jump<sup>1</sup>  
<sup>1</sup>University of North Carolina at Chapel Hill, Chapel Hill, NC, USA, <sup>2</sup>Oncocentrics, Philadelphia, PA, USA
- Abstract 34**      **Stromal cell expression of the receptor tyrosine kinase DDR2 promotes ovarian cancer metastasis**
- M. Greenwade, W.R. Grither, A.R. Hagemann, C.K. McCourt, D.G. Mutch, M.A. Powell, P.H. Thaker and K.C. Fuh  
*Washington University School of Medicine in St. Louis, St. Louis, MO, USA*
- FOCUSED PLENARY II: REDUCING COST AND PAIN  
ABSTRACTS 35-39  
11:30 a.m. – 12:30 p.m.**
- Abstract 35**      **Can the ASCO alternative payment model achieve cost savings in ovarian cancer care?**
- H.A. Moss<sup>1</sup>, M. Dinan<sup>2</sup>, M.V. Georgieva<sup>2</sup>, L.H. Hendrix<sup>2</sup> and L.J. Havrilesky<sup>1</sup>  
<sup>1</sup>Duke University Medical Center, Durham, NC, USA, <sup>2</sup>Duke Cancer Institute, Durham, NC, USA
- Abstract 36**      **Evaluation of financial toxicity in women with gynecologic malignancies: A cross-sectional study**
- E.M. Webster<sup>1</sup>, S. Chatterjee<sup>2</sup>, L. Gabor<sup>1</sup>, R.M. Vattakalam<sup>1</sup>, J.Y. Hou<sup>1</sup>, A.I. Tergas<sup>1</sup> and J.D. Wright<sup>3</sup>  
<sup>1</sup>NYP/Columbia University Medical Center, New York, NY, USA, <sup>2</sup>NYPH, Columbia University Medical Center and Weill Cornell Medical College, New York, NY, USA, <sup>3</sup>Columbia University College of Physicians and Surgeons, New York, NY, USA
- Abstract 37**      **Use of lay navigation in gynecologic oncology patients: A model to reduce costs**
- R.P. Rocconi<sup>1</sup>, P. Sharma<sup>2</sup>, A. Azuero<sup>2</sup>, J.M. Scalici<sup>1</sup>, J. Young Pierce<sup>1</sup>, N.L. Jones<sup>1</sup>, K.S. Bevis<sup>2</sup>, E.E. Partridge<sup>2</sup>, E. Kvale<sup>2</sup>, G.B. Rocque<sup>2</sup> and M. Pisu<sup>2</sup>  
<sup>1</sup>Mitchell Cancer Institute, University of South Alabama, Mobile, AL, USA, <sup>2</sup>University of Alabama at Birmingham, Birmingham, AL, USA
- Abstract 38**      **A comparison of liposomal bupivacaine to bupivacaine HCl in transversus abdominis planus block for abdominal gynecologic surgery: A randomized controlled trial**
- H. Ching<sup>1</sup>, R.F. Atkins<sup>1</sup>, E.R. Burton<sup>2</sup>, M.I. Edelson<sup>2</sup>, J.I. Sorosky<sup>2</sup> and M.S. Shahin<sup>2</sup>  
<sup>1</sup>Abington Memorial Hospital, Abington, PA, USA, <sup>2</sup>Hanjani Institute for Gynecologic Oncology, Abington Memorial Hospital, Abington, PA, USA
- Abstract 39**      **Impact of enhanced recovery after surgery (ERAS) protocol on postoperative pain control in chronic narcotic users**
- H.J. Smith, T.K.L. Boitano, T. Rushton, M.C. Johnston, C.A. Leath III and J.M. Straughn Jr.  
*University of Alabama at Birmingham, Birmingham, AL, USA*



**FOCUSED PLENARY III: NEW INSIGHTS INTO RARE TUMORS  
ABSTRACTS 40-44**

**11:30 a.m. – 12:30 p.m.**

**Abstract 40**      **KMT2D/MLL2 loss of function is a novel driver of disease recurrence in adult-type granulosa cell tumors of the ovary**

R.T. Hillman, J. Celestino, K.H. Lu, D.M. Gershenson, R. Broaddus and P.A. Futreal  
*The University of Texas MD Anderson Cancer Center, Houston, TX, USA*

**Abstract 41**      **Integrated genomic analyses distinguish leiomyosarcomas arising at distinct anatomic origins**

M.L. Anderson<sup>1</sup> and A.J. Lazar<sup>2</sup>  
<sup>1</sup>*Baylor College of Medicine, Houston, TX, USA*, <sup>2</sup>*The University of Texas MD Anderson Cancer Center, Houston, TX, USA*

**Abstract 42**      **Single-course methotrexate and single-course combined methotrexate–dactinomycin: A phase III randomized controlled clinical trial in treatment of low-risk gestational trophoblastic neoplasm**

L. Chen<sup>1</sup>, R. Yin<sup>2</sup>, L. Xi<sup>3</sup>, J. Jiang<sup>4</sup>, X. Li<sup>5</sup>, P. Qu<sup>6</sup>, B. Kong<sup>4</sup>, D. Ma<sup>7</sup>, X. Xie<sup>1</sup> and W. Lv<sup>1</sup>  
<sup>1</sup>*Women's Hospital, School of Medicine, Zhejiang University, Zhejiang, China*, <sup>2</sup>*West China Second University Hospital, Sichuan, China*, <sup>3</sup>*Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China*, <sup>4</sup>*Qilu Hospital of Shandong University, Jinan, China*, <sup>5</sup>*Shengjing Hospital of China Medical University, Shengyang, China*, <sup>6</sup>*Tianjin Central Hospital of Gynecology Obstetrics, Nankai University, Tianjin, China*, <sup>7</sup>*Tongji Hospital of Tongji Medical College, Wuhan, China*

**Abstract 43**      **The impact of uterine re-curettage on the number of chemotherapy courses in treatment of post molar gestational trophoblastic neoplasia: A randomized controlled study**

R. Hemida<sup>1</sup>, B.E. Deek<sup>1</sup>, M. Arafa<sup>1</sup>, E. Toson<sup>1</sup>, E.L. Vos<sup>2</sup>, C.W. Burger<sup>2</sup> and H.C.V. Doorn<sup>2</sup>  
<sup>1</sup>*Mansoura University, Mansoura, Egypt*, <sup>2</sup>*Erasmus University Medical Centre, Rotterdam, Netherlands*

**Abstract 44**      **Molecular profiling of ovarian germ cell tumors**

M. Stasenko<sup>1</sup>, A. Zehir<sup>1</sup>, A. Snyder<sup>1</sup>, D. Reales<sup>1</sup>, D. DeLair<sup>1</sup>, R.A. Soslow<sup>1</sup>, N.R. Abu-Rustum<sup>1</sup>, C.A. Aghajanian<sup>2</sup>, D. Feldman<sup>1</sup> and D.B. Solit<sup>1</sup>  
<sup>1</sup>*Memorial Sloan Kettering Cancer Center, New York, NY, USA*, <sup>2</sup>*Weill Cornell Medical College, New York, NY, USA*

**EDUCATION FORUM X: WELLNESS**

**ABSTRACTS 45-46**

**4:30 p.m. – 6:00 p.m.**

**Abstract 45**      **Career demands of gynecologic oncology have a substantial impact on family planning**

M. Song<sup>1</sup>, A. Kapoor<sup>1</sup>, R. Isaksson Vogel<sup>2</sup>, M.A. Geller<sup>2</sup> and D.G.K. Teoh<sup>2</sup>  
<sup>1</sup>*University of Minnesota Cancer Center, Minneapolis, MN, USA*, <sup>2</sup>*University of Minnesota, Minneapolis, MN, USA*

**Abstract 46**      **The career effects of parenting on female and male gynecologic oncologists**

L.B. Beffa<sup>1</sup>, A.R. Stuckey<sup>1</sup>, E.K. Hill<sup>2</sup>, A.K. Brown<sup>3</sup>, M.E. Gordinier<sup>4</sup>, C. Raker<sup>2</sup>, M. Clark<sup>5</sup> and K.M. Robison<sup>1</sup>  
<sup>1</sup>*Women & Infants Hospital, Brown University, Providence, RI, USA*, <sup>2</sup>*University of Iowa, Iowa City, IA, USA*, <sup>3</sup>*Hartford Hospital, Hartford, CT, USA*, <sup>4</sup>*Norton Healthcare, Louisville, KY, USA*, <sup>5</sup>*University of Massachusetts Medical Center, Worcester, MA, USA*

**Tuesday, March 27, 2018**

**SCIENTIFIC PLENARY VI: IMMUNO-ONCOLOGY**

**ABSTRACTS 47-51**

**7:30 a.m. – 8:30 a.m.**

- Abstract 47**      **Pembrolizumab in advanced recurrent endometrial cancer: A cost-effectiveness analysis**
- D.A. Barrington, S.E. Dilley, H.J. Smith and J.M. Straughn Jr.  
*University of Alabama at Birmingham, Birmingham, AL, USA*
- Abstract 48**      **Predictors of early treatment discontinuation in ovarian cancer patients on checkpoint blockade immunotherapy**
- J. Boland<sup>1</sup>, M. Martin<sup>1</sup>, N. Zecca<sup>1</sup>, A. Iasonos<sup>1</sup>, Q. Zhou<sup>1</sup>, C.A. Aghajanian<sup>1,2</sup>, P. Sabbatini<sup>1,2</sup>, K.A. Cadoo<sup>1,2</sup> and D. Zamarin<sup>1,2</sup>  
<sup>1</sup>*Memorial Sloan Kettering Cancer Center, New York, NY, USA*, <sup>2</sup>*Weill Cornell Medical College, New York, NY, USA*
- Abstract 49**      **Phase II study of pembrolizumab (pembro) combined with pegylated liposomal doxorubicin (PLD) for recurrent platinum-resistant ovarian, fallopian tube or peritoneal cancer**
- U.A. Matulonis<sup>1</sup>, W. Barry<sup>1</sup>, R.T. Penson<sup>2</sup>, P.A. Konstantinopoulos<sup>1</sup>, W. Luo<sup>1</sup>, M.A. Hoffman<sup>3</sup>, N.S. Horowitz<sup>4</sup>, S. Farooq<sup>1</sup>, D.S. Dizon<sup>5</sup>, E. Stover<sup>1</sup>, A.A. Wright<sup>1,6</sup>, S.M. Campos<sup>1</sup>, C. Krasner<sup>7</sup> and J.F. Liu<sup>1</sup>  
<sup>1</sup>*Dana-Farber Cancer Institute, Boston, MA, USA*, <sup>2</sup>*Massachusetts General Hospital/Harvard University, Boston, MA, USA*, <sup>3</sup>*Long Island Jewish Medical Center, New Hyde Park, NY, USA*, <sup>4</sup>*Brigham and Women's Hospital, Boston, MA, USA*, <sup>5</sup>*Lifespan Cancer Institute, Rhode Island Hospital, Warren Alpert Medical School of Brown University, Providence, RI, USA*, <sup>6</sup>*Harvard Medical School, Boston, MA, USA*, <sup>7</sup>*Massachusetts General Hospital, Boston, MA, USA*
- Abstract 50**      **Phase II, two-stage study of avelumab in patients with microsatellite stable (MSS), microsatellite instable (MSI) and polymerase epsilon (POLE) mutated recurrent or persistent endometrial cancer**
- P.A. Konstantinopoulos<sup>1</sup>, J.F. Liu<sup>1</sup>, W. Barry<sup>1</sup>, C. Krasner<sup>2</sup>, M.K. Buss<sup>3</sup>, M.J. Birrer<sup>4,5</sup>, S. Farooq<sup>1</sup>, S.M. Campos<sup>1</sup>, E. Stover<sup>1</sup>, S. Schumer<sup>1</sup>, A.A. Wright<sup>6</sup>, D.S. Dizon<sup>7</sup>, W. Luo<sup>1</sup>, R.T. Penson<sup>4</sup>, S.A. Cannistra<sup>3</sup>, G.F. Fleming<sup>8</sup> and U.A. Matulonis<sup>1</sup>  
<sup>1</sup>*Dana-Farber Cancer Institute, Boston, MA, USA*, <sup>2</sup>*Massachusetts General Hospital, Boston, MA, USA*, <sup>3</sup>*Beth Israel Deaconess Medical Center, Boston, MA, USA*, <sup>4</sup>*Massachusetts General Hospital/Harvard University, Boston, MA, USA*, <sup>5</sup>*University of Alabama at Birmingham, Birmingham, AL, USA*, <sup>6</sup>*Harvard Medical School, Boston, MA, USA*, <sup>7</sup>*Lifespan Cancer Institute, Rhode Island Hospital, Warren Alpert Medical School of Brown University, Providence, RI, USA*, <sup>8</sup>*University of Chicago Medical Center, Chicago, IL, USA*
- Abstract 51**      **Gene set enrichment clustering and the tumor microenvironment in primary high-grade serous ovarian cancer (HGSOC)**
- P. Cybulska<sup>1</sup>, A. Jimenez-Sanchez<sup>2</sup>, K. LaVigne<sup>1</sup>, T. Walther<sup>1</sup>, H.A. Vargas<sup>1</sup>, O. Zivanovic<sup>1</sup>, B. Weigelt<sup>1</sup>, E. Sala<sup>1</sup>, M. Miller<sup>2</sup> and A. Snyder<sup>3</sup>  
<sup>1</sup>*Memorial Sloan Kettering Cancer Center, New York, NY, USA*, <sup>2</sup>*University of Cambridge, Cambridge, United Kingdom*, <sup>3</sup>*Adaptive Biotechnologies, Seattle, WA, USA*

## SCIENTIFIC PLENARY VII: IMPROVING PATIENT EXPERIENCE AND OUTCOMES

### ABSTRACTS 52-57

8:40 a.m. – 10:00 a.m.

#### Abstract 52

#### GOG 244, The lymphedema and gynecologic cancer (LEG) study: The association between the gynecologic cancer lymphedema questionnaire (GCLQ) and lower extremity lymphedema

J. Carter<sup>1</sup>, H. Huang<sup>2</sup>, J.A. Armer<sup>3</sup>, J.W. Carlson<sup>4</sup>, S. Lockwood<sup>5</sup>, S. Nolte<sup>6</sup>, B.R. Stewart<sup>3</sup>, L. Wenzel<sup>7</sup>, J. Kauderer<sup>2</sup>, A. Hutson<sup>2</sup>, J.L. Walker<sup>8</sup>, A.C. Fleury<sup>9</sup>, J.T. Soper<sup>10</sup>, C.A. Mathews<sup>11</sup>, O. Zivanovic<sup>1</sup>, W.E. Richards<sup>12</sup>, D.S. Alberts<sup>13</sup> and R.R. Barakat<sup>1</sup>

<sup>1</sup>Memorial Sloan Kettering Cancer Center, New York, NY, USA, <sup>2</sup>Gynecologic Oncology Group Statistical and Data Center, Buffalo, NY, USA, <sup>3</sup>University of Missouri, Columbia, MO, USA, <sup>4</sup>Mercy Clinic - Women's Oncology, Springfield, MO, USA, <sup>5</sup>SGNO, Fort Worth, TX, USA, <sup>6</sup>Abington Memorial Hospital, Abington, PA, USA, <sup>7</sup>University of California, Irvine, Irvine, CA, USA, <sup>8</sup>The University of Oklahoma, Oklahoma City, OK, USA, <sup>9</sup>Women's Cancer Center of Nevada, Las Vegas, NV, USA, <sup>10</sup>University of North Carolina at Chapel Hill, Chapel Hill, NC, USA, <sup>11</sup>Women & Infants Hospital, Brown University, Providence, RI, USA, <sup>12</sup>Lewis Cancer & Research Pavilion @ St. Joseph's Candler, Savannah, GA, USA, <sup>13</sup>The University of Arizona Cancer Center, Tucson, AZ, USA

#### Abstract 53

#### Patient-reported symptom burden and functional recovery before and after enhanced recovery after surgery (ERAS) implementation: A comparison between open and minimally invasive surgery

L.A. Meyer<sup>1</sup>, Q. Shi<sup>1</sup>, J.D. Lasala<sup>1</sup>, A.M. Nick<sup>2</sup>, M.D. Iniesta<sup>1</sup>, A.M. Siverand<sup>1</sup>, C. Corzo<sup>1</sup>, X.S. Wang<sup>1</sup>, K.H. Lu<sup>1</sup> and P.T. Ramirez<sup>1</sup>

<sup>1</sup>The University of Texas MD Anderson Cancer Center, Houston, TX, USA, <sup>2</sup>St. Thomas Medical Partners, University of Tennessee Health Sciences Center, Nashville, TN, USA

#### Abstract 54

#### Gestational trophoblastic disease electronic consults: What do patients and physicians want to know?

R. Nitecki<sup>1</sup>, N.S. Horowitz<sup>2</sup>, K.M. Elias<sup>2</sup>, D.P. Goldstein<sup>3</sup> and R.S. Berkowitz<sup>2</sup>

<sup>1</sup>Brigham and Women's Hospital/Harvard Medical School, Boston, MA, USA, <sup>2</sup>Brigham and Women's Hospital, Boston, MA, USA, <sup>3</sup>Brigham and Women's Hospital/Harvard University, Boston, MA, USA

#### Abstract 55

#### It's like "magic": The mobile application for genetic information on cancer

M.A. Geller, R. Isaksson Vogel, H.Y. Lee, K. Niendorf, H.W. Lee and S.V. Petzel  
University of Minnesota, Minneapolis, MN, USA

#### Abstract 56

#### Rethinking cervical cancer screening guidelines in an aging U.S. population

S.E. Dilley, J.A. O'Donnell, H.J. Smith, S. Bae and W. Huh  
University of Alabama at Birmingham, Birmingham, AL, USA

#### Abstract 57

#### Patient-reported outcomes after surgery for endometrial carcinoma: Prevalence of lower extremity lymphedema after sentinel lymph node mapping (SLNM) compared to lymphadenectomy

M.M. Leitao Jr.<sup>1</sup>, N.R. Gómez-Hidalgo<sup>2</sup>, A. Iasonos<sup>1</sup>, Q. Zhou<sup>1</sup>, M. Mezzancello<sup>1</sup>, K. Chang<sup>1</sup>, J. Ward<sup>1</sup>, R.R. Barakat<sup>1</sup>, D.S. Chi<sup>1</sup>, K. Long Roche<sup>1</sup>, Y. Sonoda<sup>1</sup>, C.L. Brown<sup>1</sup>, J.J. Mueller<sup>1</sup>, G.J. Gardner<sup>1</sup>, E. Jewell<sup>1</sup>, V. Broach<sup>1</sup>, O. Zivanovic<sup>1</sup>, S.C. Dowdy<sup>3</sup>, A. Mariani<sup>3</sup> and N.R. Abu-Rustum<sup>1</sup>  
<sup>1</sup>Memorial Sloan Kettering Cancer Center, New York, NY, USA, <sup>2</sup>NYP/Columbia University Medical Center, New York, NY, USA, <sup>3</sup>Mayo Clinic, Rochester, MN, USA

## SCIENTIFIC PLENARY VIII: LAST BUT NOT LEAST...

### ABSTRACTS 58-61

10:00 a.m. – 11:00 a.m.

#### Abstract 58

**A novel site-specific proteomic screening test for ovarian cancer in a large prospective multi-institutional clinical study**

R.P. Rocconi, J.M. Scalici, L. Schambeau, L. Pannell and M.A. Finan  
*Mitchell Cancer Institute, University of South Alabama, Mobile, AL, USA*

#### Abstract 59

**Evidence for synthetic lethality between bevacizumab and chemotherapy in advanced, p53 null endometrial cancers**

A.R. Mallen<sup>1</sup>, V.L. Filiaci<sup>2</sup>, D.A. Levine<sup>3</sup>, K. Thiel<sup>4</sup>, C.A. Aghajanian<sup>5</sup>, X. Meng<sup>6</sup>, E. Devor<sup>6</sup>, K.N. Moore<sup>7</sup>, M.A. Powell<sup>8</sup>, A.A. Secord<sup>9</sup>, K.S. Tewari<sup>10</sup>, D.P. Bender<sup>6</sup>, A.R. Stuckey<sup>11</sup>, J.M. Fowler<sup>12</sup>, S.B. Dewdney<sup>13</sup> and K.K. Leslie<sup>6</sup>

<sup>1</sup>Moffitt Cancer Center-University of South Florida, Tampa, FL, USA, <sup>2</sup>Gynecologic Oncology Group Statistical and Data Center, Buffalo, NY, USA, <sup>3</sup>New York University School of Medicine, New York, NY, USA, <sup>4</sup>University of Iowa Carver College of Medicine, Iowa City, IA, USA, <sup>5</sup>Weill Cornell Medical College, New York, NY, USA, <sup>6</sup>University of Iowa Hospitals and Clinics, Iowa City, IA, USA, <sup>7</sup>The University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA, <sup>8</sup>Washington University School of Medicine in St. Louis, St. Louis, MO, USA, <sup>9</sup>Duke Cancer Institute, Durham, NC, USA, <sup>10</sup>University of California Irvine Medical Center, Orange, CA, USA, <sup>11</sup>Women & Infants Hospital, Brown University, Providence, RI, USA, <sup>12</sup>The Ohio State University, James Cancer Hospital, Columbus, OH, USA, <sup>13</sup>Rush University Medical Center, Chicago, IL, USA

#### Abstract 60

**Randomized trial of adjuvant chemotherapy versus concurrent chemoradiotherapy in early-stage cervical cancer after radical surgery: A Chinese Gynecologic Oncology Group study (CSEM-002)**

D. Weng<sup>1</sup>, H. Wang<sup>1</sup>, C. Zhu<sup>2</sup>, B. Cui<sup>3</sup>, C. Wang<sup>1</sup>, K. Li<sup>1</sup>, Q. Gao<sup>1</sup>, X. Cheng<sup>2</sup>, X. Yang<sup>3</sup>, J. Jiang<sup>3</sup>, Y. Zhang<sup>3</sup>, B. Kong<sup>3</sup>, X. Xie<sup>2</sup> and D. Ma<sup>1</sup>

<sup>1</sup>Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, <sup>2</sup>Women's Hospital, School of Medicine, Zhejiang University, Zhejiang, China, <sup>3</sup>Qilu Hospital, Shandong University, Jinan, China

#### Abstract 61

**Come back in six months, or never? Defining surveillance and survivorship in gynecologic malignancies with an evidence-based approach**

R.L. Dood, Y. Zhao, S. Armbruster, C.J. LaFargue, O.D. Lara, G.Z. Dal Molin, A.K. Sood and K.A. Baggerly  
*The University of Texas MD Anderson Cancer Center, Houston, TX, USA*

## FEATURED POSTERS

- Abstract 62**      **Benign surgery performed by gynecologic oncologists: Is selection bias altering our ability to measure surgical quality?**
- E.L. Barber<sup>1</sup>, A.L. Alexander<sup>1</sup>, S. Shahabi<sup>2</sup> and E.C. Rossi<sup>3</sup>  
*<sup>1</sup>Northwestern University Feinberg School of Medicine, Chicago, IL, USA, <sup>2</sup>Western CT Health Network/Danbury Hospital, Danbury, CT, USA, <sup>3</sup>University of North Carolina at Chapel Hill, Chapel Hill, NC, USA*
- Abstract 63**      **Racial disparities in hereditary gynecologic cancer risk assessment: What and why?**
- D.A. Barrington, S. Batra, G. McGwin, T.B. Turner, A. Brown, M.B. Farmer, J.M. Straughn Jr. and C.A. Leath III  
*University of Alabama at Birmingham, Birmingham, AL, USA*
- Abstract 64**      **The utility of preoperative PET/CT in the detection of extrauterine disease in high-risk endometrial cancer: A prospective study**
- K.I. Stewart<sup>1</sup>, B. Chasen<sup>1</sup>, W.D. Erwin<sup>1</sup>, N.D. Fleming<sup>1</sup>, S.N. Westin<sup>1</sup>, M. Frumovitz<sup>1</sup>, P.T. Ramirez<sup>1</sup>, S.M. Dioun<sup>2</sup>, K.H. Lu<sup>1</sup>, F. Wong<sup>1</sup> and P.T. Soliman<sup>1</sup>  
*<sup>1</sup>The University of Texas MD Anderson Cancer Center, Houston, TX, USA, <sup>2</sup>Montefiore Medical Center, Bronx, NY, USA*
- Abstract 65**      **A comprehensive genomic analysis of neuroendocrine carcinoma of gynecologic and breast tumors**
- P.C. Mayor<sup>1</sup>, L. Gay<sup>2</sup>, K. Fan<sup>3</sup>, P.J. Frederick<sup>1</sup>, R.N. Eskander<sup>4</sup>, J. Sun<sup>2</sup>, J.S. Ross<sup>5</sup>, R. Kurzrock<sup>6</sup>, S.N. Akers<sup>1</sup>, S.B. Lele<sup>1</sup>, K. Odunsi<sup>1</sup>, E. Zsiros<sup>1</sup> and J.A. Elvin<sup>2</sup>  
*<sup>1</sup>Roswell Park Cancer Institute, Buffalo, NY, USA, <sup>2</sup>Foundation Medicine, Inc., Cambridge, MA, USA, <sup>3</sup>University of Buffalo, Buffalo, NY, USA, <sup>4</sup>UCSD Rebecca and John Moores Cancer Center, La Jolla, CA, USA, <sup>5</sup>Albany Medical College, Albany, NY, USA, <sup>6</sup>University of California San Diego, La Jolla, CA, USA*
- Abstract 66**      **Development and validation of a risk calculator for adverse perioperative outcomes for women with ovarian cancer**
- S. Cham, A.I. Tergas, J.Y. Hou, C. St. Clair, C. V. Ananth, D.L. Hershman and J.D. Wright  
*NYP/Columbia University Medical Center, New York, NY, USA*
- Abstract 67**      **Nedaplatin and paclitaxel compared with carboplatin and paclitaxel for patients with platinum-sensitive recurrent ovarian cancer**
- L. Ge<sup>1</sup>, N. Li<sup>2</sup> and L.Y. Wu<sup>2</sup>  
*<sup>1</sup>National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, <sup>2</sup>Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China*

- Abstract 68**      **A subgroup of cases with a high immunogenic profile in homologous recombination-proficient high-grade serous ovarian carcinoma: Possible candidates for checkpoint blockade therapy**
- K. Hasegawa<sup>1</sup>, H. Matsushita<sup>2</sup>, K. Oda<sup>2</sup>, S. Yamamoto<sup>3</sup>, K. Asada<sup>2</sup>, A. Yabuno<sup>1</sup>, A. Nishijima<sup>2</sup>, T. Karasaki<sup>2</sup>, Y. Ikeda<sup>1</sup>, K. Fujiwara<sup>1</sup>, H. Aburatani<sup>3</sup> and K. Kakimi<sup>2</sup>  
*<sup>1</sup>Saitama Medical University International Medical Center, Hidaka, Japan, <sup>2</sup>The University of Tokyo Hospital, Tokyo, Japan, <sup>3</sup>Research Center for Advanced Science and Technology, The University of Tokyo, Tokyo, Japan*
- Abstract 69**      **Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy as initial treatment of ovarian, fallopian tube, and primary peritoneal cancer: Preliminary results of a phase II randomized clinical trial**
- T.P. Diaz-Montes, F. El-Sharkawy, V. Gushchin, H.S. Ryu, M. Sittig and A. Sardi  
*Mercy Medical Center, Baltimore, MD, USA*
- Abstract 70**      **Utilization of preoperative PET-CT and pelvic MRI reduces multimodality therapy in the care of women with early-stage cervical carcinoma**
- E.J. Diver<sup>1</sup>, E.M. Hinchcliff<sup>1</sup>, A.A. Gockley<sup>2</sup>, A. Melamed<sup>1</sup>, L. Contrino<sup>3</sup>, S. Feldman<sup>3</sup> and W.B. Growdon<sup>2</sup>  
*<sup>1</sup>Massachusetts General Hospital, Boston, MA, USA, <sup>2</sup>Harvard Medical School, Boston, MA, USA, <sup>3</sup>Brigham and Women's Hospital, Boston, MA, USA*
- Abstract 71**      **Identification of ovarian cancer patients for immunotherapy by concurrent assessment of tumor mutation burden (TMB), microsatellite instability (MSI) status, and targetable genomic alterations (GA)**
- J. Feinberg<sup>1</sup>, J.A. Elvin<sup>2</sup>, S. Bellone<sup>1</sup> and A.D. Santin<sup>1</sup>  
*<sup>1</sup>Yale University School of Medicine, New Haven, CT, USA, <sup>2</sup>Foundation Medicine, Inc., Cambridge, MA, USA*
- Abstract 72**      **Evaluation of circulating tumor DNA in patients with endometrial cancer harboring somatic PIK3CA or KRAS mutations: A potential high-risk factor for recurrence**
- D. Shintani<sup>1</sup>, T. Hihara<sup>2</sup>, A. Ogasawara<sup>3</sup>, A. Yabuno<sup>3</sup>, K. Fujiwara<sup>1</sup>, K. Tai<sup>2</sup> and K. Hasegawa<sup>1</sup>  
*<sup>1</sup>Research Center for Genomic Medicine, Saitama Medical University, Hidaka, Japan, <sup>2</sup>Tsukuba Research Laboratories, Eisai Co., Ltd, Tsukuba, Japan, <sup>3</sup>Saitama Medical University International Medical Center, Hidaka, Japan*
- Abstract 73**      **Tackling the opioid crisis: Reduced postoperative oral and intravenous opioid use after implementation of an enhanced recovery after surgery (ERAS) program in gynecologic oncology patients**
- H.J. Gray<sup>1</sup>, C. Rind<sup>1</sup>, E.S. Wu<sup>1</sup>, B.A. Goff<sup>1</sup>, H.K. Tamimi<sup>1</sup>, K. Pennington<sup>2</sup> and R.R. Urban<sup>1</sup>  
*<sup>1</sup>University of Washington Medical Center, Seattle, WA, USA, <sup>2</sup>University of Washington School of Medicine, Seattle, WA, USA*

**Abstract 74****GOG 8035: Nuclear *BRCA1* loss may identify a poor prognostic subgroup of women with locally advanced cervical cancer treated with cisplatin-based chemoradiation: An NRG Oncology study**

T.C. Longoria<sup>1</sup>, M. Sill<sup>2</sup>, B.J. Monk<sup>3</sup>, J. Fruehauf<sup>4</sup>, S.Y. Liao<sup>5</sup>, R. Emerson<sup>6</sup>, J.H. Kim<sup>1</sup>, R.S. Mannel<sup>7</sup>, Y.C. Lee<sup>8</sup>, C.A. Mathews<sup>9</sup>, L.M. Randall<sup>1</sup>, K.M. Darcy<sup>10</sup>, M.J. Birrer<sup>11</sup> and K.S. Tewari<sup>1</sup>

<sup>1</sup>University of California Irvine Medical Center, Orange, CA, USA, <sup>2</sup>Gynecologic Oncology Group Statistical and Data Center, Buffalo, NY, USA, <sup>3</sup>University of Arizona Cancer Center, Phoenix, AZ, USA, <sup>4</sup>University of California, Irvine, Orange, CA, USA, <sup>5</sup>St. Joseph's Hospital and Medical Center, Urbana, IL, USA, <sup>6</sup>Indiana University School of Medicine, Indianapolis, IN, USA, <sup>7</sup>The University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA, <sup>8</sup>SUNY Downstate, Brooklyn, NY, USA, <sup>9</sup>Women & Infants Hospital, Brown University, Providence, RI, USA, <sup>10</sup>Gynecologic Cancer Center of Excellence, John P. Murtha Cancer Center, Walter Reed National Military Medical Center, Uniformed Services University of the Health Sciences, Annandale, VA, USA, <sup>11</sup>Massachusetts General Hospital/Harvard University, Boston, MA, USA

**Abstract 75****Initial safety and activity findings from a phase IB escalation study of mirvetuximab soravtansine, a folate receptor alpha (FR $\alpha$ -targeting antibody-drug conjugate (ADC), with pembrolizumab in platinum-resistant epithelial ovarian cancer (EOC) patients**

U.A. Matulonis<sup>1</sup>, K.N. Moore<sup>2</sup>, L.P. Martin<sup>3</sup>, I.B. Vergote<sup>4</sup>, C.M. Castro<sup>5</sup>, L. Gilbert<sup>6</sup>, A. Berkenblit<sup>7</sup>, M.J. Birrer<sup>8</sup> and D.M. O'Malley<sup>9</sup>

<sup>1</sup>Dana-Farber Cancer Institute, Boston, MA, USA, <sup>2</sup>The University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA, <sup>3</sup>Fox Chase Cancer Center, Philadelphia, PA, USA, <sup>4</sup>University Hospital Leuven, Leuven, Belgium, <sup>5</sup>Massachusetts General Hospital, Boston, MA, USA, <sup>6</sup>McGill University Health Centre, Montreal, QC, Canada, <sup>7</sup>ImmunoGen, Inc., Waltham, MA, USA, <sup>8</sup>Massachusetts General Hospital/Harvard University, Boston, MA, USA, <sup>9</sup>The Ohio State University, James Cancer Hospital, Columbus, OH, USA

**Abstract 76****Concordance of germline multigene panel testing with prior microsatellite instability and immunohistochemistry analyses in endometrial cancer patients**

K. Jasperson<sup>1</sup>, C.R. Espenschied<sup>1</sup>, H. Hampel<sup>2</sup>, P. Reineke<sup>1</sup>, T. Pesaran<sup>1</sup>, V. Speare<sup>1</sup>, J. Profato<sup>1</sup> and I.M. Frayling<sup>3</sup>

<sup>1</sup>Ambry Genetics, Aliso Viejo, CA, USA, <sup>2</sup>The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA, <sup>3</sup>Cardiff University, Cardiff, United Kingdom

**Abstract 77****Sentinel lymph node mapping (SLNM) in endometrioid endometrial cancer: Does it work in the real world?**

O. Valieva<sup>1</sup>, D.M. Greer<sup>2</sup>, J.J.F. Kram<sup>2</sup>, E. Schmit<sup>1</sup>, E.L. Dickson<sup>1</sup> and S.A. Kamelle<sup>2</sup>

<sup>1</sup>Aurora Health Care, Gurnee, IL, USA, <sup>2</sup>Aurora Health Care, Milwaukee, WI, USA

**Abstract 78****Germline *BRCA* mutation rate in Southern California Latina women**

L.J. Hong<sup>1</sup>, R. Gonzalez<sup>2</sup>, S. Abu-Tabikh<sup>2</sup>, L. Cristiano<sup>2</sup>, J. Unternaehrer-Hamm<sup>1</sup> and Y.J.M. Ioffe<sup>1</sup>

<sup>1</sup>Loma Linda University School of Medicine, Loma Linda, CA, USA, <sup>2</sup>Loma Linda University Medical Center, Loma Linda, CA, USA

**Abstract 79****Phase I trial of Vigil<sup>®</sup> personalized engineered autologous tumor cells (EATC) in ovarian cancer**

R.P. Rocconi<sup>1</sup>, J.M. Scalici<sup>1</sup>, M. Barve<sup>2</sup>, L. Manning<sup>3</sup>, G. Wallraven<sup>3</sup>, N. Senzer<sup>3</sup> and J. Nemunaitis<sup>3</sup>

<sup>1</sup>Mitchell Cancer Institute, University of South Alabama, Mobile, AL, USA, <sup>2</sup>Texas Oncology, P.A., Dallas, TX, USA, <sup>3</sup>Gradalis, Inc., Dallas, TX, USA

- Abstract 80**      **A prospective, randomized control trial evaluating the impact of backfill versus spontaneous voiding trial on discharge time for gynecologic oncology patients undergoing laparoscopic hysterectomy**
- M.R. Davis<sup>1</sup>, K.E. Barletta<sup>2</sup>, A.T. Ford<sup>3</sup>, R. Nitecki<sup>2</sup>, K.M. Elias<sup>4</sup>, M.J. Worley Jr.<sup>1</sup>, R.S. Berkowitz<sup>4</sup>, M.G. Muto<sup>5</sup>, N.S. Horowitz<sup>4</sup> and C.M. Feltmate<sup>4</sup>  
*<sup>1</sup>Brigham and Women's Hospital/Harvard University, Boston, MA, USA, <sup>2</sup>Brigham and Women's Hospital/Harvard Medical School, Boston, MA, USA, <sup>3</sup>Emory University, Atlanta, GA, USA, <sup>4</sup>Brigham and Women's Hospital, Boston, MA, USA, <sup>5</sup>Dana-Farber Cancer Institute, Boston, MA, USA*
- Abstract 81**      **Adoptive dendritic cell transfer following platinum-based chemotherapy extends overall host survival in a preclinical model of metastatic ovarian cancer**
- A. Buskwofie<sup>1</sup>, E. Teran-Cabanillas<sup>2</sup>, T. Sandoval Medina<sup>2</sup> and J.R. Cubillos-Ruiz<sup>2</sup>  
*<sup>1</sup>NYPH, Columbia University Medical Center and Weill Cornell Medical College, New York, NY, USA, <sup>2</sup>Weill Cornell Medical College, New York, NY, USA*
- Abstract 82**      **Zoptec: Phase III randomized controlled study comparing zoptarelin with doxorubicin as second line therapy for locally advanced, recurrent, or metastatic endometrial cancer (NCT01767155)**
- D.S. Miller<sup>1</sup>, A. Oaknin<sup>2</sup>, R.M. Wenham<sup>3</sup>, A.M. Oza<sup>4</sup>, I.B. Vergote<sup>5</sup>, A. Westermann<sup>6</sup>, D.L. Tait<sup>7</sup> and H. Gabra<sup>8</sup>  
*<sup>1</sup>The University of Texas Southwestern Medical Center, Dallas, TX, USA, <sup>2</sup>GEICO (Grupo Espanol de Investigacion en Cancer de Ovario), Barcelona, Spain, <sup>3</sup>H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA, <sup>4</sup>Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada, <sup>5</sup>University Hospital Leuven, Leuven, Belgium, <sup>6</sup>Academic Medical Centre, Amsterdam, Netherlands, <sup>7</sup>Levine Cancer Institute, Carolinas Medical Center, Charlotte, NC, USA, <sup>8</sup>Imperial College Healthcare NHS Trust, London, United Kingdom*
- Abstract 83**      **Vaginal brachytherapy is associated with improved overall survival in stage IB endometrioid endometrial carcinoma: A propensity matched, National Cancer Data Base study**
- M.M. AlHilli<sup>1</sup>, S. Amarnath<sup>1</sup> and S.C. Dowdy<sup>2</sup>  
*<sup>1</sup>The Cleveland Clinic Foundation, Cleveland, OH, USA, <sup>2</sup>Mayo Clinic, Rochester, MN, USA*
- Abstract 84**      **Favorable tumor immunophenotype is associated with homologous recombination deficiency in ovarian carcinoma**
- C.B. Morse<sup>1</sup>, M.N. Toukatly<sup>1</sup>, M.I. Harrell<sup>2</sup>, K.J. Agnew<sup>3</sup>, S.S. Bernards<sup>3</sup>, B.M. Norquist<sup>2</sup>, K. Pennington<sup>3</sup>, M.R. Kilgore<sup>1</sup>, R.L. Garcia<sup>1</sup> and E.M. Swisher<sup>1</sup>  
*<sup>1</sup>University of Washington Medical Center, Seattle, WA, USA, <sup>2</sup>University of Washington, Seattle, WA, USA, <sup>3</sup>University of Washington School of Medicine, Seattle, WA, USA*
- Abstract 85**      **Comparative efficacy and tolerability of the PARP inhibitors, olaparib 300 mg tablets BID, niraparib 300 mg capsules QD and rucaparib 600 mg tablets BID as maintenance treatment in BRCA-mutated (BRCAm) platinum-sensitive relapsed ovarian**
- A. Sackeyfio<sup>1</sup>, F. Nussey<sup>2</sup>, M. Friedlander<sup>3</sup> and E. Pujade-Lauraine<sup>4</sup>  
*<sup>1</sup>AstraZeneca, Cambridge, United Kingdom, <sup>2</sup>Western General Hospital, Edinburgh, United Kingdom, <sup>3</sup>Prince of Wales Hospital, Randwick, Australia, <sup>4</sup>Hôpital Hotel Dieu, Paris, France*



**Abstract 86****Immune checkpoint expression, microsatellite instability, and mutational burden: Identifying immune biomarker phenotypes in uterine cancer**

N.L. Jones<sup>1</sup>, J. Xiu<sup>2</sup>, T. Herzog<sup>3</sup> and I. Winer<sup>4</sup>

<sup>1</sup>Mitchell Cancer Institute, University of South Alabama, Mobile, AL, USA, <sup>2</sup>Caris Life Sciences, Irving, TX, USA, <sup>3</sup>UC Health Barrett Cancer Center, Cincinnati, OH, USA, <sup>4</sup>Wayne State University, Detroit, MI, USA

**Abstract 87****Mutational burden, tumor immune checkpoint expression, and microsatellite instability in gynecologic malignancies: Implications for immune therapy**

I. Winer<sup>1</sup>, N.L. Jones<sup>2</sup>, J. Xiu<sup>3</sup>, A. Ellerbrock<sup>3</sup>, J. Brown<sup>4</sup> and T. Herzog<sup>5</sup>

<sup>1</sup>Wayne State University, Detroit, MI, USA, <sup>2</sup>Mitchell Cancer Institute, University of South Alabama, Mobile, AL, USA, <sup>3</sup>Caris Life Sciences, Irving, TX, USA, <sup>4</sup>Levine Cancer Institute, Carolinas Medical Center, Charlotte, NC, USA, <sup>5</sup>UC Health Barrett Cancer Center, Cincinnati, OH, USA

**Abstract 88****Improving the efficacy of PARP inhibition with a novel ATR inhibitor, ATRN119, in ovarian high-grade serous cancers**

E. George<sup>1</sup>, H. Kim<sup>2</sup>, L.R. Butler<sup>3</sup>, M.A. Morgan<sup>2</sup>, O. Gilad<sup>3</sup>, E.J. Brown<sup>1</sup> and F. Simpkins<sup>2</sup>

<sup>1</sup>Hospital of the University of Pennsylvania, Philadelphia, PA, USA, <sup>2</sup>University of Pennsylvania, Philadelphia, PA, USA, <sup>3</sup>Atrin Pharmaceuticals, Doylestown, PA, USA

**Abstract 89****System-wide implementation of a perioperative practice-changing bundle to lower surgical site infections in gynecologic oncology: Outcome effect and impact of variations in compliance**

A.S. O'Shea, B.F. Lees, R. Harrison, R. Spencer, L.M. Barroilhet, E.M. Hartenbach, L.W. Rice, S.L. Rose and A.N. AL-Niaimi

University of Wisconsin School of Medicine and Public Health, Madison, WI, USA

**Abstract 90****CA-125 is a useful predictor of disease status in uterine carcinosarcoma**

M.S. Ross<sup>1</sup>, C.K. Chandler<sup>1</sup>, E. Elishaev<sup>1</sup>, N. Siripong<sup>2</sup>, J. Berger<sup>1</sup>, J.L. Kelley III<sup>1</sup> and S.E. Taylor<sup>1</sup>

<sup>1</sup>Magee-Womens Hospital of UPMC, Pittsburgh, PA, USA, <sup>2</sup>University of Pittsburgh/Magee-Womens Hospital, Pittsburgh, PA, USA